logo
Share SHARE
FONT-SIZE Plus   Neg

Gilead's Sovaldi Shows Efficacy & Safety In Chronic Hepatitis C Patients

Gilead Sciences, Inc. (GILD) reported data from two Phase 2 studies and a compassionate access study, wherin a regimen containing once-daily Sovaldi 400 mg was administered to treat chronic hepatitis C virus or HCV infection in patients with advanced liver disease.

The first study, named Study GS-US-334-0125, is an ongoing open-label Phase 2 trial assessing HCV patients with cirrhosis and portal hypertension, with or without decompensation, who were randomized 1:1 to an immediate treatment arm in which Sovaldi and ribavirin or RBV was administered for 48 weeks or to a deferred treatment arm in which this regimen was started after a 24-week observation period.

Out of the 22 patients who completed 24 weeks of therapy, 95 percent achieved virologic suppression on treatment. Further, patients taking Sovaldi-based therapy experienced trends in clinical and laboratory parameter improvements compared to patients in the observation arm; and 80% of participants were treatment-experienced

Study GS-US-334-0126, was a single-arm open-label Phase 2 study in which patients with established recurrent HCV infection following liver transplantation received up to 24 weeks of therapy with Sovaldi plus RBV. The majority of patients had genotype 1-HCV infection and 88 percent were treatment-experienced. According to the company, seventy percent of patients in this study achieved SVR12.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Canadian power company Emera has agreed to buy Teco Energy Inc for $27.55 per share in cash as part of efforts to expand into Florida and New Mexico. The announcement sent Teco shares surging 28 percent in after-hours trade on the New York Stock Exchange. Xiaomi Corp., nicknamed the "Apple of China" is planning to launch laptops, a report by Bloomberg said. The Chinese brand has been pausing a direct challenge to major smart phone brands in Asian markets in the recent years. It has planned to win over China, India and Brazil markets those together would account for one third of the worldwide sales. Value-priced fashion apparel and accessories retailer Cato Corp. (CATO) Thursday announced a four percent increase in comparable store sales for August. Sales were for the four week period was up five percent to $67 percent from $63.6 million last year. For the thirty weeks ended August 29, the...
comments powered by Disqus
Follow RTT